Skip to NavigationSkip to content

Immupharma and Avion sign agreement for lupus drug Lupuzor

Published on 29/11/19 at 12:58pm

Immupharma has signed a development agreement with Avion Pharmaceuticals to acquire the licensing rights for Lupuzor, a peptide therapeutic and autophagy immunomodualtor for auto-immune disease systemic lupus erythematosus (SLE or lupus).

Under their agreement, the companies will co-develop the drug and allow the registration for marketing in the US, Europe and elsewhere. Avion will commercialise the drug exclusively for the US while Immupharma will retain all the rights for outside the US.

Dimitri Dimitriou, the Chief Executive Officer at ImmuPharma, said: “We are delighted to be entering into this partnership with Avion” adding that the company “look forward to a long and successful relationship with the Avion team”.

Art Deas, the CEO of Avion, also commented: “We believe that Lupuzor has a unique position within lupus that sets it apart from the competition and we are delighted to be extending our footprint. With approximately 1.5 million patients in the US suffering from lupus, there is a significant unmet need for a safe and effective drug for this debilitating disease that we believe Lupuzor can meet”.

The optimised Phase 3 clinal trial of the drug is scheduled to begin in 2020, over a period of one year, and is expected to include patients in the US and Europe. It will follow a trial design agreed by the two companies and the FDA.

Conor Kavanagh

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches